{"nctId":"NCT02987543","briefTitle":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","startDateStruct":{"date":"2017-02-06","type":"ACTUAL"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"count":387,"armGroups":[{"label":"Olaparib","type":"EXPERIMENTAL","interventionNames":["Drug: olaparib"]},{"label":"Enzalutamide OR abiraterone acetate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: enzalutamide","Drug: abiraterone acetate"]}],"interventions":[{"name":"olaparib","otherNames":["Lynparza"]},{"name":"enzalutamide","otherNames":["XTANDI"]},{"name":"abiraterone acetate","otherNames":["ZYTIGA"]},{"name":"abiraterone acetate","otherNames":["ZYTIGA"]},{"name":"enzalutamide","otherNames":["XTANDI"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n1. Histologically confirmed diagnosis of prostate cancer.\n2. Documented evidence of metastatic castration resistant prostate cancer (mCRPC).\n3. Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and/or enzalutamide) for the treatment of metastatic prostate cancer and/or CRPC .\n4. Ongoing therapy with LHRH analog or bilateral orchiectomy.\n5. Radiographic progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy).\n6. Qualifying HRR mutation in tumor tissue.\n\nExclusion criteria\n\n1. Any previous treatment with PARP inhibitor, including olaparib.\n2. Subjects who have any previous treatment with DNA-damaging cytotoxic chemotherapy, except if for non-prostate cancer indication and last dose \\> 5 years prior to randomization.\n3. Other malignancy (including MDS and MGUS) within the last 5 years except: adequately treated non-melanoma skin cancer or other solid tumors curatively treated with no evidence of disease for ≥5 years.\n4. Subjects with known brain metastases.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"130 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Confirmed Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) - Cohort A Only","description":"ORR is the percentage of patients with at least one visit response of Complete response (CR) or Partial response (PR), in their soft tissue disease assessed by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), in the absence of progression on bone scan assessed by Prostate Cancer Working Group 3 (PCWG3)). Per RECIST v1.1, CR=Disappearance of all target lesions; PR = \\>=30% decrease in the sum of diameters of target lesions; For each treatment group, ORR is the number of patients with a CR and PR.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]},{"type":"SECONDARY","title":"Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A+B","description":"The time from randomisation until the date of objective radiological disease progression (by RECIST 1.1 and Prostate Cancer Working Group 3 (PGWG-3)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.82","spread":null},{"groupId":"OG001","value":"3.52","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Pain Progression - Cohort A Only","description":"Time from randomisation to time point at which worsening in pain is observed (ie date of pain progression - date of randomisation + 1). Based on average Brief Pain Inventory - short form (BPI-SF) worst pain \\[Item 3\\] and Analgesic Quantification Algorithm \\[AQA\\] score.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"9.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS) - Cohort A Only","description":"Number of Participants with Overall Survival (OS) - Cohort A only.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"57","spread":null}]},{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Radiological Progression Free Survival (rPFS) by Blinded Independent Central Review (BICR) - Cohort A Only","description":"The time from randomisation until the date of objective radiological disease progression (determined by RECIST 1.1 (soft tissue) and Prostate Cancer Working Group 3 (PCWG-3) (bone)) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from randomised therapy or received another anti-cancer therapy prior to progression. Progression is defined using (i) Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue, as a \\>=20% increase in the sum of diameters of target lesions and an absolute increase of \\>=5mm taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters; (ii) Prostate Cancer Working Group 3 (PGWG-3) for bone as \\>= 2 new bone lesions on the 1st week 8 scan compared to baseline. The confirmatory scan, \\>=6 weeks later, must show \\>=2 more new bone lesions (for a total of \\>=4 new bone lesions since baseline).","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.39","spread":null},{"groupId":"OG001","value":"3.55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":94,"n":256},"commonTop":["Nausea","Anaemia","Decreased appetite","Fatigue","Constipation"]}}}